Skip to content
Butenafine
Lotrimin Ultra, Mentax (butenafine) is a small molecule pharmaceutical. Butenafine was first approved as Mentax on 1996-10-18. It is used to treat mycoses, tinea pedis, and tinea versicolor in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
skin and connective tissue diseasesD017437
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Lotrimin ultra, Mentax (generic drugs available since 2017-11-16, discontinued: Mentax-tc)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Butenafine hydrochloride
Tradename
Company
Number
Date
Products
LOTRIMIN ULTRABayerN-021307 OTC2001-12-07
1 products, RLD, RS
MENTAXMylanN-020524 RX1996-10-18
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
athletes footANDA2023-05-31
lotrimin ultraNew Drug Application2022-11-22
mentaxNew Drug Application2018-06-15
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
mycoses—D009181B35-B49
tinea pedisEFO_0007512D014008B35.3
tinea versicolorEFO_0007439D014010B36.0
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D01: Antifungals for dermatological use
— D01A: Antifungals for topical use
— D01AE: Other antifungals for topical use in atc
— D01AE23: Butenafine
HCPCS
No data
Clinical
Clinical Trials
2 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Migraine disordersD008881EFO_0003821G43——1——1
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Anorexia nervosaD000856EFO_0004215F50.0————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBUTENAFINE
INNbutenafine
Description
Butenafine is trimethylamine in which hydrogen atoms attached to different methyl groups are substituted by 1-naphthyl and 4-tert-butylphenyl groups. It is an inhibitor of squalene epoxidase, an enzyme responsible for the creation of sterols needed in fungal cell membranes, and is used as its hydrochloride salt for treatment of dermatological fungal infections. It has a role as an EC 1.14.13.132 (squalene monooxygenase) inhibitor and an antifungal drug. It is a tertiary amine and a member of naphthalenes.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CN(Cc1ccc(C(C)(C)C)cc1)Cc1cccc2ccccc12
Identifiers
PDB—
CAS-ID101828-21-1
RxCUI47461
ChEMBL IDCHEMBL990
ChEBI ID3238
PubChem CID2484
DrugBankDB01091
UNII ID91Y494NL0X (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 277 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
2,892 adverse events reported
View more details